Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$16.64 +1.2%	$18.73	$13.52 ▼ $35.25	$1.66B	2.22	2.54 million shs	1.71 million shs
MRNA Moderna	$24.73 -2.4%	$29.15	$23.15 ▼ $81.61	$9.86B	1.83	8.77 million shs	12.98 million shs
PFE Pfizer	$24.97 -0.7%	$24.74	$20.92 ▼ $30.43	$142.93B	0.52	44.55 million shs	43.91 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	+1.22%	+1.77%	-23.39%	-1.42%	-38.62%
MRNA Moderna	-2.45%	-11.39%	-27.58%	-5.07%	-69.72%
PFE Pfizer	-0.74%	-1.30%	+0.73%	+7.70%	-13.71%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BEAM Beam Therapeutics	2.0278 of 5 stars	3.5	0.0	0.0	0.0	2.1	2.5	0.6
MRNA Moderna	4.4994 of 5 stars	4.0	2.0	0.0	4.6	2.7	2.5	0.6
PFE Pfizer	4.8761 of 5 stars	2.2	3.0	4.2	4.5	3.4	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	3.07	Buy	$48.45	191.19% Upside
MRNA Moderna	2.04	Hold	$42.88	73.40% Upside
PFE Pfizer	2.39	Hold	$28.12	12.63% Upside

Current Analyst Ratings Breakdown

Latest PFE, MRNA, and BEAM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	MRNA Moderna	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underperform ➝ Underperform	$18.00 ➝ $15.00
8/6/2025	BEAM Beam Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$25.00 ➝ $21.00
8/6/2025	PFE Pfizer	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$25.00 ➝ $26.00
8/6/2025	PFE Pfizer	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$32.00 ➝ $33.00
8/6/2025	PFE Pfizer	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$27.00 ➝ $28.00
8/4/2025	MRNA Moderna	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$40.00 ➝ $31.00
8/1/2025	MRNA Moderna	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$32.00
8/1/2025	MRNA Moderna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$26.00
8/1/2025	MRNA Moderna	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$40.00
8/1/2025	MRNA Moderna	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight ➝ Equal Weight	$32.00
7/22/2025	MRNA Moderna	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underperform ➝ Underperform	$26.00 ➝ $25.00

(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$63.52M	26.50	N/A	N/A	$10.35 per share	1.61
MRNA Moderna	$3.24B	2.97	N/A	N/A	$24.16 per share	1.02
PFE Pfizer	$63.83B	2.22	$4.33 per share	5.76	$15.66 per share	1.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$376.74M	-$4.50	N/A	N/A	N/A	-661.31%	-43.15%	-31.06%	11/4/2025 (Estimated)
MRNA Moderna	-$3.56B	-$7.53	N/A	N/A	N/A	-94.31%	-25.96%	-20.09%	11/6/2025 (Estimated)
PFE Pfizer	$8.03B	$1.88	13.28	8.24	0.89	16.84%	21.42%	9.12%	11/4/2025 (Estimated)

Latest PFE, MRNA, and BEAM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	BEAM Beam Therapeutics	-$1.04	-$1.00	+$0.04	-$1.00	$13.29 million	$8.47 million
8/5/2025	Q2 2025	PFE Pfizer	$0.58	$0.78	+$0.20	$0.51	$13.43 billion	$14.65 billion
8/1/2025	Q2 2025	MRNA Moderna	-$2.99	-$2.13	+$0.86	-$2.13	$116.26 million	$142.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	6.89%	N/A	91.49%	16 Years

Latest PFE, MRNA, and BEAM Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	N/A	6.75	6.75
MRNA Moderna	N/A	3.93	3.77
PFE Pfizer	0.65	1.16	0.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
MRNA Moderna	75.33%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.50%
MRNA Moderna	11.00%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	101.16 million	97.62 million	Optionable
MRNA Moderna	5,800	389.08 million	346.28 million	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

PFE, MRNA, and BEAM Headlines

Recent News About These Companies

Understanding Pfizer's Long Strangle Options Strategy Amid Market Volatility

August 26 at 8:25 PM | sohu.comS

Pfizer put volume heavy and directionally bearish

August 26 at 8:25 PM | msn.com

Pfizer: A New Era Beyond COVID Revenue

August 26 at 3:23 PM | sohu.comS

Smart Money Is Betting Big In PFE Options

August 26 at 3:23 PM | benzinga.com

Pfizer (NYSE:PFE) Trading Down 2.2% - Here's What Happened

August 26 at 1:39 PM | marketbeat.com

Schwerin Boyle Capital Management Inc. Sells 28,940 Shares of Pfizer Inc. $PFE

August 26 at 9:20 AM | marketbeat.com

WealthTrust Axiom LLC Increases Stock Holdings in Pfizer Inc. $PFE

August 26 at 8:48 AM | marketbeat.com

Pfizer: Emerging Stronger Post-COVID Revenue Decline

August 26 at 8:43 AM | sohu.comS

Corebridge Financial Inc. Sells 38,513 Shares of Pfizer Inc. $PFE

August 26 at 8:38 AM | marketbeat.com

Pfizer lays off 100 employees in Seattle area

August 26 at 2:52 AM | geekwire.comG

Pfizer: Resilience Beyond COVID Revenue Challenges

August 26 at 2:11 AM | sohu.comS

Pfizer cuts 100 jobs in Bothell, Washington

August 26 at 2:11 AM | msn.com

Pfizer's Credibility Discount: A Clear Buying Opportunity

August 25 at 12:50 AM | seekingalpha.com

A person walks in front of an electronic stock board showing Japan's Nikkei index at a securities f…

Asian shares decline following Wall Street's dip

...

August 25 at 10:45 PM | marketbeat.com

Moderna stock falls, Pfizer dips on COVID vaccine ban speculation

August 25 at 5:42 PM | in.investing.com

Pfizer Inc. $PFE Shares Sold by Anson Funds Management LP

August 25 at 8:11 AM | marketbeat.com

Comerica Bank Boosts Stake in Pfizer Inc. $PFE

August 25 at 8:10 AM | marketbeat.com

MetLife Investment Management LLC Trims Holdings in Pfizer Inc. $PFE

August 25 at 7:47 AM | marketbeat.com

Pfizer Inc. $PFE Shares Sold by Synovus Financial Corp

August 25 at 7:39 AM | marketbeat.com

Groupe la Francaise Has $3.97 Million Holdings in Pfizer Inc. $PFE

August 25 at 5:40 AM | marketbeat.com

1832 Asset Management L.P. Sells 9,955,299 Shares of Pfizer Inc. $PFE

August 25 at 5:23 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PFE, MRNA, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$16.64 +0.20 (+1.22%)

Closing price 08/26/2025 04:00 PM Eastern

Extended Trading

$16.78 +0.14 (+0.84%)

As of 04:13 AM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Moderna NASDAQ:MRNA

$24.73 -0.62 (-2.45%)

Closing price 08/26/2025 04:00 PM Eastern

Extended Trading

$24.85 +0.12 (+0.49%)

As of 04:24 AM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Pfizer NYSE:PFE

$24.96 -0.18 (-0.70%)

Closing price 08/26/2025 03:59 PM Eastern

Extended Trading

$24.96 0.00 (0.00%)

As of 04:24 AM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time